Anti-CEACAM6 Fluorescent Agent for Breast Tumor Margin Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current breast cancer surgery techniques face challenges in identifying and removing breast tumors with negative margins during lumpectomy, leading to high reoperation rates and increased risks of recurrence, as existing fluorescence imaging agents lack specificity for tumor margins relative to normal tissues.
Innovation Solution
Development of a humanized anti-CEACAM6 monoclonal antibody imaging agent conjugated with near-infrared fluorescent dyes, such as IRDye800CW, for real-time visualization of breast tumors during surgery, utilizing the SurgVision clinical imaging platform to guide surgical removal and assess tumor margins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional fluorescence imaging agents are used for tumor visualization, then real-time imaging during surgery is achieved, but specificity for tumor margins relative to normal tissues is insufficient
Solution Approach 1:
The patent applies local quality by creating a fluorescent imaging agent with heterogeneous structure: the antibody portion provides tumor-specific targeting (high specificity) while the fluorescent dye portion provides optical detection capability. This localized functional differentiation within the conjugate enables precise tumor margin detection without false positives from normal tissues.
Solution Approach 2:
The patent employs composite materials by conjugating two distinct components: a monoclonal antibody (providing biological specificity for CEACAM6 antigen) and a fluorescent dye (providing optical detectability). This composite structure combines the targeting precision of antibodies with the real-time visualization capability of fluorescent dyes, resolving the contradiction between detection precision and reliability.
2Productivity
If breast conserving surgery is performed without advanced imaging guidance, then operative risk and recovery time are reduced, but reoperation rates increase due to undetectable residual tumor cells
Solution Approach 1:
The patent applies preliminary action by administering the fluorescent imaging agent before surgery and allowing it to accumulate in tumor cells expressing CEACAM6 antigen. This pre-surgical preparation enables the surgeon to visualize tumor margins in real-time during the procedure, ensuring complete resection while maintaining surgical efficiency and avoiding reoperations.
Solution Approach 2:
The patent implements feedback by providing real-time optical visualization of tumor tissue during surgery. The fluorescent signal serves as continuous feedback to the surgeon about the presence of tumor cells at the resection margins, allowing immediate adjustment of the resection boundary to achieve complete removal while preserving healthy tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CEACAM6 imaging agent enables precise detection and removal of breast tumors with high sensitivity and specificity, potentially reducing reoperation rates and improving surgical outcomes by providing real-time visualization of tumor margins during breast conserving surgery.
Implementation Method 1
humanized anti-CEACAM6 monoclonal antibody imaging agents
Implementation Method 2
the first detectable label comprises any dye (such as, for example IRdye800, AlexaFluor 790, ZW-800 (Frangioni et al), Indocyanine Green, and 50456) that emits fluorescent light that is detectable on a clinical optical NIRF imager
Data Source
AI summary
Disclosed are novel detectable imaging agents that can bind to a novel biomarker for cancer and methods of their use in the resection of a tumor.